Metabolic effects of pecan nut consumption in adults with Obesity: a randomized controlled trial

Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo0 个研究点开始时间: 2019年9月24日最近更新: 2023年5月29日

适应症

试验速览

暂无简介。

•Volunteers aged 20 to 59 years; body mass index (BMI) equal to or greater than 30 kg / m² due to excess body fat; who agreed to participate voluntarily in the study; and that they would be willing to follow the proposed recommendations.

•Participants with: 1) psychiatric disorders, history of cancer, endocrine disorders (adrenal diseases, thyroid diseases, polycystic ovarian syndrome, diabetes mellitus and dyslipidemia in drug and non-drug treatment), spoliation status (fever, malabsorption syndrome, surgery), inflammatory, infectious, autoimmune, renal, cardiovascular, hepatic (cirrhosis, hepatitis, and hepatic insufficiency) diseases; 2) use of weight-loss, appetite-suppressing, immunosuppressive, anti-inflammatory, corticosteroid, antibiotic, hypolipidemic, antidiabetic, anticoagulant, antihypertensive, hormonal (except stable contraceptive use for at least 6 months); 3) frequent consumption of nuts, including peanuts and baru almonds (one or more times in the week); 4) allergy or food intolerance to any type of nuts (including peanuts or baru almonds); 5) use of dietary supplements; 6) alcoholics, smokers or drug abuse; 7) women in climacteric, pregnant and nursing mothers; 8) performing restrictive diet or dietary treatment.

发起方

Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo